The diversity of cancer is generated through genetic alterations as well as by epigenetic events regulated by the tumor microenvironment. At the apex of this hierarchy are cancer stem cells (CSCs) which are characterized by their ability to self-renew, as well as to generate the cells constituting the tumor bulk. CSCs contribute to cancer metastasis and therapeutic resistance [1]. It is now clear that cellular interactions within the tumor microenvironment regulate both the cancer stem cell and bulk cell components which play an important role in tumor progression and metastasis. Deconvoluting the role of various components in the human cancer microenvironment and elucidating the mechanism of interaction has proved to be a great challenge. Recent studies have demonstrated that different immune components including Th22 cells [2] and myeloid derived suppressor cells (MDSCs)[3] are involved in the control of cancer stemness. Chemokines are important players in the immune responses. For some time it has been known that chemokines are able to target and recruit specific immune subsets into the microenvironment. For example, CXCL12 [4] and CXCL20 [5] mediate tumor trafficking of plasmacytoid dendritc cells (4) and regulatory T cells [5], respectively. These immune cell subsets can mediate immunosuppression and consequently promote cancer progression. Interestingly, chemokines may directly target tumor cells and affect tumorigenesis. CXCL8 (IL-8)[6] has been demonstrated to be involved in cancer stem cell biology and cancer cell metastasis. Furthering this work, Zhu et al, in this issue of Oncoscience, describe a new role for cancer stem cell-derived CCL5 in ovarian cancer metastasis.

Ovarian cancer stem cells are enriched in cell fractions expressing CD133+ and ALDH-1+[3, 7]. In an attempt to examine the role of CCL5 in cancer metastasis, Dr. Zhu and colleagues employed several complementary approaches to test the hypothesis that cancer stem cellderived CCL5 played a role in endowing CSCs with invasive properties. They found that in the presence of CD133+ CSCs, CD133-cancer cells undergo an epithelialmesenchymal transition (EMT)-like process and display enhanced metastatic capacity in in vitro assays as well as in vivo xenografts. They demonstrated that CD133+, but not CD133-cancer cells, expressed CCL5, with CCL5 signaling blockade abrogating and recombinant CCL5 mimicking these effects. In further support of the potential clinical significance of CCL5 and its receptors in